A recent longitudinal study found that GLP-1–based agonist action may not only be an effective treatment for T2D but also prevent or delay disease manifestation in at-risk individuals: Liraglutide treatment reduced the risk of T2D manifestation in obese individuals and individuals who had a body mass index of more than 27 and had hypertension or dyslipidaemia; after 160 weeks, the liraglutide-treated group (n = 1472) had a smaller percentage of the population with diagnosed T2D (2% versus 6%) than the placebo-treated control group (n = 738)99. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.